Skip to content
Open access

MicroRNA Expression in Macrophages Regulates Antibody-Dependent Effector Function and B-cell Lymphoma Therapy

Oct 2026 · Cancer Research Communications · Vol 6, pp. 2631 - 2643 · 0 citations · 41 references
Medicine

Abstract

Abstract CD163+ tumor-associated macrophages (TAM) are associated with poor response to immunochemotherapy in patients with diffuse large B-cell lymphoma and comprise a significant proportion of the tumor microenvironment (TME). Targeting these TAMs to reverse immunosuppression is an attractive approach for improving treatment response rates. A change in microRNA (miRNA) expression has the potential to modify hundreds of genes by interacting with multiple messenger RNA (mRNA) targets, thereby altering the wider cellular transcriptional profile. The manipulation of miRNAs that control macrophage behavior may switch the global transcriptomic profiles of immunosuppressive macrophages to more activated, antitumor states, resulting in the reversal of immune resistance and enhancement of monoclonal antibody (mAb) therapy. Our studies show a significant upregulation of miR-142-5p in immunosuppressive macrophages stimulated with IL4/IL13 compared with lipopolysaccharide (LPS)/IFNγ-stimulated macrophages and nonpolarized controls. This upregulation of miR-142-5p in macrophages stimulated with immunoinhibitory cytokines IL10 and TGFβ was also demonstrated. Inhibition of miR-142-5p expression in IL4/IL13-stimulated macrophages led to a significant increase in FcγRIIIA, CD40, and CD47 expression with enhanced phagocytosis of chronic lymphocytic leukemia (CLL) cells opsonized with rituximab when compared with nontransfected controls. Expression of miR-142-5p in diagnostic samples of patients with diffuse large B-cell lymphoma (DLBCL) was assessed using miRScope assays. These were combined with immunohistochemistry (IHC) staining of CD206 to identify immunosuppressive macrophages. Combination of high miR-142-5p and CD206 expression correlated with a reduction in progression-free survival (PFS) following standard rituximab containing chemotherapy regimens in 38 patients. Together, these studies indicate the potential of targeting miRNA to repolarize macrophages and improve treatment success. Significance: The manipulation of macrophage polarization within the TME has the potential to enhance immunotherapies used across many different cancer types. The use of miRNA inhibitors to target the immune system in a cell-specific way using antibody oligonucleotide conjugates has the potential to reduce toxicity historically associated with miRNA therapeutics and change the phenotype of cells at the transcriptomic level.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.